the FDA approved several new drugs and new indications, including Roche's two blockbuster subcutaneous formulations, Eli Lilly's IL-13 antibody, and Johnson & Johnson's IL-23 antibody.

9.2-9.8 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

8.26-9.1 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

8.19-8.25 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed.

This article will inventory the anti-tumor targets in the GPCR family and the therapeutic drugs that have been marketed.

7.1-7.7 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

6.24-6.30 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

6.17-6.23 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

6.10-6.16 Global Drug R&D Progress & Pharmaceutical Transaction Trends.